Combination therapy improves pathology indices in diffuse mesangial sclerosis

Pediatr Int. 2019 May;61(5):517-520. doi: 10.1111/ped.13840. Epub 2019 May 15.

Authors

Koji Nagatani¹, Masatoshi Hayashi¹

Affiliation

¹ Department of Pediatrics, Uwajima City Hospital, Uwajima, Ehime, Japan.

PMID: 31090167
DOI: 10.1111/ped.13840

No abstract available

Keywords: WT1 mutation; angiotensin-converting enzyme inhibitor; cyclosporin A; diffuse mesangial sclerosis.

Publication types

Case Reports

MeSH terms

Cyclosporine / therapeutic use*
Drug Administration Schedule
Drug Therapy, Combination
Enalapril / therapeutic use*
Enzyme Inhibitors / therapeutic use*
Female
Humans
Infant
Nephrotic Syndrome / diagnosis
Nephrotic Syndrome / drug therapy*
Nephrotic Syndrome / pathology*
Sclerosis / diagnosis
Sclerosis / drug therapy*
Sclerosis / pathology*

Substances

Enzyme Inhibitors
Enalapril
Cyclosporine

Supplementary concepts

Mesangial sclerosis, diffuse